Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhrm Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Notice of Annual General Meeting and Board Changes

Fri, 27th Jun 2014 07:05

RNS Number : 6913K
Phorm Corporation Limited
27 June 2014
 

27 June 2014

 

Phorm Corporation Limited

("Phorm" or the "Company")

 

Notice of Annual General Meeting and Board Changes

 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces that its forthcoming Annual General Meeting ("AGM") will be held at 11.00 a.m. (London time) on Thursday 24 July 2014 at the offices of Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London EC1A 2FG.

The formal notice convening and outlining details of the AGM is being posted to shareholders today and, once posted, will also be made available to download from the Investor Relations section of the Company's website at www.phorm.com.

Board Changes

Phorm is also pleased to announce that Mr Johannes Minho Roth will be appointed as a Non-Executive Director of the Company on 24 July 2014, subject to shareholders' approval at the abovementioned AGM. Mr Roth is the founding director and partner at FiveT Capital Holding AG, a Switzerland-based innovative financial holdings firm. He has many years experience of international markets and technology businesses including acting as Chief Executive Officer at FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG. Mr Roth also holds a Masters degree (diploma) in Economics from Hohenheim University, in Germany.

In addition, the Company announces that Christophe Delorme will step down from the Board with effect from the conclusion of the abovementioned AGM to focus on his other business interests, including his role as CEO of NFT Investment PTE Ltd.

Kent Ertugrul, Chairman and CEO of Phorm commented:

"We are delighted to welcome Johannes to the Phorm Board. His valuable experience of international markets and technology businesses will assist with the group's future growth and development.

"We are grateful for the important contribution Christophe has made to Phorm and wish him well in his future endeavours.

"The composition of the Board is reviewed on a regular basis and it remains our intention to appoint an independent Chairman at the appropriate stage in the Company's commercial development."

Additional information on Mr Johannes Minho Roth

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

Johannes Minho Roth (aged 35)

Current Directorships/Partnerships

Past Directorships/Partnerships (last 5 years)

FiveT Capital Holding AG

None

FiveT Capital AG

 

Insilico Biotechnology AG

 

Plug Power, Inc.

 

Amorfix Life Sciences Ltd

 

Fanorakel AG

 

 

As noted above, Mr Roth is the founding director and partner at FiveT Capital AG which is currently interested in 25,545,000 ordinary shares of nil par value each in the capital of Phorm, representing approximately 4.12 per cent. of the Company's existing issued share capital.

There is no other information that is required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.

-Ends-

 

For further information please contact:

 

Phorm Corporation Limited

Andy Croxson (analysts and investors) +44 (0) 203 397 6001

 

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

 

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

 

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's industry leading technology enables its Internet Service Provider ("ISP") partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

 

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

 

Phorm, under a predecessor holding company, was admitted to the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGZVNVMGDZM
Date   Source Headline
14th Apr 201610:00 amRNSUpdate and Resignation of Nominated Adviser
16th Mar 201612:37 pmRNSIssue of US$500,000 of Convertible Loan Notes
16th Mar 20167:00 amRNSIssue of US$500,000 of Convertible Loan Notes
25th Feb 20168:02 amRNSFunding Update and Statement re Suspension
25th Feb 20167:55 amRNSSuspension - Phorm Corporation Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.